M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Evaluation of Malignant Breast Lesions Using High-resolution Readout-segmented Diffusion-weighted Echo-planar Imaging: Comparison with Pathology.
Ayami Ohno Kishimoto,Masako Kataoka,Mami Iima,Maya Honda,Kanae Miyake,Akane Ohashi,Rie Ota,Tatsuki R. Kataoka,Takaki Sakurai,Masakazu Toi,Kaori Togashi +10 more
TL;DR: Investigation of the performance of high resolution-diffusion-weighted imaging using readout-segmented echo-planar imaging in visualizing malignant breast lesions and evaluating their extent, using pathology as a reference found malignant mass lesions depicted with excellent agreement with the pathological evaluation.
Proceedings ArticleDOI
Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE
Nadia Harbeck,Stephen Albert Johnston,Peter A. Fasching,Miguel Martín,Masakazu Toi,Priya Rastogi,Chuan-gui Song,David Molthrop,Jacqueline Vuky,Toshinari Yamashita,Georgina Garnica Jaliffe,Mahmut Gumus,Desiree Headley,Ran Wei,Susana Barriga,Maria Jose Muñoz,Michael Method,Valerie Andre,Hans Kreipe,Joyce O'Shaughnessy +19 more
TL;DR: Harbeck et al. as discussed by the authors evaluated endocrine therapy with or without abemaciclib in patients with node positive, HR+, HER2-, high risk early breast cancer, resulted in a statistically significant improvement in invasive disease-free survival (IDFS) at a pre-planned interim analysis.
Journal ArticleDOI
A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease.
Richard S. Finn,Véronique Diéras,Karen A. Gelmon,Nadia Harbeck,Stephen E. Jones,Maria Koehler,Miguel Martin,Hope S. Rugo,Seock-Ah Im,Masakazu Toi,Eric Gauthier,Xin Huang,Sophia Randolph,Dennis J. Slamon +13 more
TL;DR: Palbociclib (PD-0332991) is an orally bioavailable selective inhibitor of CDK4/6 that prevents DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
Journal ArticleDOI
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Hidetoshi Kawaguchi,Norikazu Masuda,Takahiro Nakayama,Kenjiro Aogi,Keisei Anan,Yoshinori Ito,Shoichiro Ohtani,Nobuaki Sato,Shigehira Saji,Toshimi Takano,Eriko Tokunaga,Seigo Nakamura,Yoshie Hasegawa,Masaya Hattori,Tomomi Fujisawa,Satoshi Morita,Miki Yamaguchi,Hiroko Yamashita,Toshinari Yamashita,Yutaka Yamamoto,Daisuke Yotsumoto,Masakazu Toi,Shinji Ohno +22 more
TL;DR: In ER+/HER2− patients receiving F500 as a second-line or later therapy, treatment line, advanced age, no prior palliative chemotherapy use, and a longer period from ABC diagnosis to F500 use were associated with longer TTF.
Journal ArticleDOI
An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer
TL;DR: The data indicate that in basal-like breast cancer cells, IL-6 exhibits a paracrine effect to positively regulate cell proliferation, and demonstrates that cancer cells can secrete signaling molecules, such as IL- 6, to support the proliferation of other cancer cells.